Pancreatic Cancer Research

ResearcherTokushima UniversityActive in the last 2 years

Mitsuo Shimada

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1255-4783; OpenAlex author ID A5066565101, A5135215235. Sources: OpenAlex.

Their work

Papers
14 (first author 4, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
37
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 2 papers · 2015: none · 2016: none · 2017: 2 papers · 2018: none · 2019: none · 2020: 2 papers · 2021: 4 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 14

  1. An Exosomal Signature for Preoperative Detection of Occult Liver Metastasis in Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.3840↗
  2. Outcomes of remnant pancreatic resection for recurrent pancreatic cancer Last author DOI 10.21203/rs.3.rs-4026151/v1↗
  3. Malnutrition by European Society for Clinical Nutrition and Metabolism criteria predicts prognosis in patients with gastrointestinal and hepatobiliary-pancreat… Co-author DOI 10.1016/j.clnesp.2021.01.023↗
  4. Significance of frailty in prognosis after surgery in patients with pancreatic ductal adenocarcinoma. First author DOI 10.1186/s12957-021-02205-6↗
  5. Value of the CRP-albumin ratio in patients with resectable pancreatic cancer. Last author DOI 10.2152/jmi.68.244↗
  6. Value of the fibrinogen-platelet ratio in patients with resectable pancreatic cancer. Last author DOI 10.2152/jmi.68.342↗
  7. Impact of phase angle on postoperative prognosis in patients with gastrointestinal and hepatobiliary-pancreatic cancer. Co-author DOI 10.1016/j.nut.2020.110891↗
  8. Cancer-associated adipocytes promote pancreatic cancer progression through SAA1 expression. Co-author DOI 10.1111/cas.14527↗
  9. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Co-author DOI 10.1111/cas.13113↗
  10. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. Co-author DOI 10.1186/s13046-017-0509-1↗
  11. Changes of immunological parameters with administration of Japanese Kampo medicine (Juzen-Taihoto/TJ-48) in patients with advanced pancreatic cancer. First author DOI 10.1007/s10147-013-0529-6↗
  12. Valproic acid enhances the anti-tumor effect of pegylated interferon-α towards pancreatic cancer cell lines. First author PMID 24982347↗
  13. The novel hypoxic cytotoxin, TX-2098 has antitumor effect in pancreatic cancer; possible mechanism through inhibiting VEGF and hypoxia inducible factor-1α targ… Last author DOI 10.1016/j.yexcr.2012.03.013↗
  14. Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells. First author DOI 10.1007/s10147-011-0246-y↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tetsuya Ikemoto · 10 shared papers, 2011–2024 · strength 0.94
  2. Yu Saito · 8 shared papers, 2011–2024 · strength 0.91
  3. Shinichiro Yamada · 3 shared papers, 2021–2024 · strength 0.50
  4. Takayuki Noma · 2 shared papers, 2024–2026 · strength 0.49
  5. Masaaki Nishi · 3 shared papers, 2020–2021 · strength 0.35
  6. Yusuke Arakawa · 2 shared papers, 2021 · strength 0.27
  7. Jingyang Yin · 1 shared paper, 2026 · strength 0.26
  8. Mitsuro Kanda · 1 shared paper, 2026 · strength 0.26
  9. Caiming Xu · 1 shared paper, 2026 · strength 0.26
  10. Vincent M. Chung · 1 shared paper, 2026 · strength 0.26
  11. Ajay Goel · 1 shared paper, 2026 · strength 0.26
  12. Song Cheol Kim · 1 shared paper, 2026 · strength 0.26
  13. Daniel D. Von Hoff · 1 shared paper, 2026 · strength 0.26
  14. Hiroki Teraoku · 1 shared paper, 2024 · strength 0.23
  15. Sonoko Yasui‐Yamada · 2 shared papers, 2020–2021 · strength 0.22
  16. Nozomi Aotani · 2 shared papers, 2020–2021 · strength 0.22
  17. Yasuhiro Hamada · 2 shared papers, 2020–2021 · strength 0.22
  18. Shuichi Iwahashi · 3 shared papers, 2011–2014 · strength 0.12
  19. Kazuyoshi Noda · 1 shared paper, 2020 · strength 0.10
  20. Tetsuji Takayama · 1 shared paper, 2020 · strength 0.10
  21. Masanori Takehara · 1 shared paper, 2020 · strength 0.10
  22. Haruo Iguchi · 2 shared papers, 2017 · strength 0.09
  23. Masaaki Oka · 2 shared papers, 2017 · strength 0.09
  24. Tomio Ueno · 2 shared papers, 2017 · strength 0.09
  25. Takashi Hatori · 2 shared papers, 2017 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.